TABLE OF CONTENTS
Volume 12, Issue 4 (July 2006)
Top of page
Top of page
Top of page
Editorial
Top of pagePapers
Valuing biotechnology companies using the price earnings ratio
Jacqueline Loh and Robert Brooks
J Commer Biotechnol 12: 254-260; doi:10.1057/palgrave.jcb.3040175
An overview of trends in multilateral environmental agreements with an impact on biotechnology and research in Asia and the Pacific
Frankie Keller and Darryl R J Macer
J Commer Biotechnol 12: 261-273; doi:10.1057/palgrave.jcb.3040176
What you give is what you get: Investment in European biotechnology
William Bains
J Commer Biotechnol 12: 274-283; doi:10.1057/palgrave.jcb.3040177
Ticking time bomb: Poorly managed product safety
Greg Meline and Chris Albani
J Commer Biotechnol 12: 284-293; doi:10.1057/palgrave.jcb.3040178
Marketspace
Cancer remains the dominant disease target for biotech through to 2010
Fleur Pijpers and Mark J Belsey
J Commer Biotechnol 12: 294-298; doi:10.1057/palgrave.jcb.3040179
